Dishman Carbogen Amcis Ltd (DCAL) is currently trading at 151.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Dishman Carbogen Amcis is an integrated CDMO and marketable‑molecules manufacturer operating global development and manufacturing facilities across India, Switzerland, France, Netherlands and China, offering development, hi‑potency API manufacturing, ADC/linker/payload services and drug‑product capabilities under the Dishman and Carbogen Amcis brands. Q1 FY27 showed a soft quarter: consolidated revenue was INR 6,776 million (down 4% YoY) and EBITDA fell to INR 600 million due to a postponed order and FX headwinds; management highlighted the deferred order would likely shift revenue and operating profit into later quarters, impacting quarter‑to‑quarter comparability materially. Balance sheet and refinancing actions are central: net debt ex‑leases was CHF 153.6 million at quarter‑end, and shareholders approved promoter‑level external commercial borrowing up to CHF 200 million at ~4% to prepay high‑cost India debt; this refinancing is expected to reduce interest burden and improve margins for Dishman Carbogen Amcis. Management has proactively strengthened commercial capabilities — hiring Angela Ameriks as Global Chief Commercial Officer and building new sales leadership in India, EMEA and U.S. West Coast — to capture RFP momentum, convert SPRINT early‑phase wins and accelerate tech transfers from Carbogen to lower‑cost Dishman India sites. Regulatory and capability milestones materially de‑risk market access: recent MFDS (Korea) inspection success, two EDQM CEPs in Europe, ANSM approval for French site and China local GMP clearance open new revenue channels and validate Dishman Carbogen Amcis' global compliance posture.

Over the past 52 weeks, Dishman Carbogen Amcis Ltd has traded between a low of ₹129.00 and a high of ₹305.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Dishman Carbogen Amcis Ltd has a market capitalization of approximately 2,372.13. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Dishman Carbogen Amcis Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 146.79 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,372.13 Cr, Dishman Carbogen Amcis Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Dishman Carbogen Amcis Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Dishman Carbogen Amcis Ltd is 146.79. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The company informed exchanges that it allotted 3,800 non-convertible debentures at its meeting held on October 15, 2026.

The company reported a consolidated net loss of ₹57.88 crore for the quarter ended June 30, 2026, compared with a profit of ₹23.41 crore in Q1 FY26.

The board approved raising ECB up to CHF 200 million from Aamanya AG, a promoter group company, revising the earlier proposed limit of CHF 135 million.

The board approved FY26 audited results, recommended re-appointing T R Chadha & Co. LLP as statutory auditors, raised the ECB limit to CHF 200 million, and increased the overall borrowing limit to ₹4,000 crore (subject to shareholder approval).